BioWa, Lonza sign deal with Pfizer for antibody development

08/1/2013 | Pharmaceutical Business Review Online

Lonza and BioWa have granted Pfizer the right to use their Potelligent CHOK1SV cell line technology in the research and development of antibodies. The Potelligent CHOK1SV cell line can be used to develop antibodies that function in whole blood and have cytotoxic effects even at low antigen levels.

View Full Article in:

Pharmaceutical Business Review Online

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN